Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LY75


Brief Information

Name:Lymphocyte antigen 75
Target Synonym:LY75,CD205,Lymphocyte Antigen 75,C-Type Lectin Domain Family 13 Member B,CLEC13B,DEC-205,CD205 Antigen,Gp200-MR6,Ly-75
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LY5-H52H3 Human Human LY75 / CD205 Protein, His Tag
LY5-M52H5 Mouse Mouse LY75 / CD205 Protein, His Tag (MALS verified)
ACRO Quality

Part of Bioactivity data

The purity of Mouse LY75, His Tag (Cat. No. LY5-M52H5) is more than 90% and the molecular weight of this protein is around 210-255 kDa verified by SEC-MALS.

  • Background
    lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
  • Clinical and Translational Updates
  • Please contact us via if you have any question on this product.

Synonym Name

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6


Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rasdegafusp alfa CDX-1401 Phase 2 Clinical Ludwig Institute For Cancer Research Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Melanoma; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Astrocytoma; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Oligodendroglioma; Anemia, Refractory; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Glioblastoma; Colonic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Skin Melanoma Details
Oberotatug ravtansine OBT-076; MEN1309/OBT076; MEN-1309 Phase 1 Clinical Oxford Biotherapeutics Ltd, Menarini Solid tumours; Head and Neck Neoplasms; Carcinoma, Adenoid Cystic; Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message